Body mass index (BMI) is largely investigated as a prognostic and predictive factor in triple-negative breast cancer (TNBC). Overweight and obesity are linked to a variety of pathways regulating tumor-promoting functions, including the DNA damage response (DDR). The DDR physiologically safeguards genome integrity but, in a neoplastic background, it is aberrantly engaged and protects cancer cells from chemotherapy. We herein verified the role of BMI on a previously assessed association between DDR biomarkers and pathological complete response (pCR) in TNBC patients treated with neoadjuvant chemotherapy (NACT).
In this retrospective analysis 54 TNBC patients treated with NACT were included. The relationship between DDR biomarkers, namely phosphorylated H2A Histone Family Member X (γ-H2AX) and phosphorylated checkpoint kinase 1 (pChk1), and pCR was reconsidered in light of BMI data. The Pearson’s Chi-squared test of independence (2-tailed) and the Fisher Exact test were employed to assess the relationship between clinical-molecular variables and pCR. Uni- and multivariate logistic regression models were used to identify variables impacting pCR. Internal validation was carried out.
We observed a significant association between elevated levels of the two DDR biomarkers and pCR in patients with BMI < 25 (p = 0.009 and p = 0.022 for γ-H2AX and pChk1, respectively), but not in their heavier counterpart. Results regarding γ-H2AX were confirmed in uni- and multivariate models and, again, for leaner patients only (γ-H2AXhigh vs γ-H2AXlow: OR 10.83, 95% CI: 1.79–65.55, p = 0.009). The consistency of this finding was confirmed upon internal validation.
The predictive significance of γ-H2AX varies according to BMI status. Indeed, elevated levels of γ-H2AX seemed associated with lower pCR rate only in leaner patients, whereas differences in pCR rate according to γ-H2AX levels were not appreciable in heavier patients. Larger investigations are warranted concerning the potential role of BMI as effect modifier of the relationship between DDR-related biomarkers and clinical outcomes in TNBC.
Orecchioni S, Reggiani F, Talarico G, Bertolini F. Mechanisms of obesity in the development of breast cancer. Discov Med. 2015;20:121–8. PubMed
Vici P, Di Benedetto A, Ercolani C, Pizzuti L, Di Lauro L, Sergi D, et al. Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis. Oncotarget. 2015. doi: 10.18632/oncotarget.6001 [Epub ahead of print]. PubMedPubMedCentral
Yu CH. Resampling methods: concepts, applications, and justification. Pract Assess Res Eval. 2003;8(19):1–16.
von Minckwitz G, Fontanella C. Comprehensive Review on the Surrogate Endpoints of Efficacy Proposed or Hypothesized in the Scientific Community Today. J Natl Cancer Inst Monogr. 2015;2015(51):29–31. CrossRef
Barba M, Pizzuti L, Sperduti I, Natoli C, Gamucci T, Sergi D, et al. Body mass index and treatment outcomes in metastatic breast cancer patients treated with eribulin. J Cell Physiol. 2015. doi: 10.1002/jcp.25213 [Epub ahead of print].
Vici P, Sperati F, Maugeri-Saccà M, Melucci E, Di Benedetto A, Di Lauro L, et al. p53 status as effect modifier of the association between pre-treatment fasting glucose and breast cancer outcomes in non diabetic, HER2 positive patients treated with trastuzumab. Oncotarget. 2014;5:10382–92. CrossRefPubMedPubMedCentral
Janssen I, Heymsfield SB, Allison DB, Kotler DP, Ross R. Body mass index and waist circumference independently contribute to the prediction of nonabdominal, abdominal subcutaneous, and visceral fat. Am J Clin Nutr. 2002;75(4):683–8. PubMed
- Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer
Luigi Di Lauro
Anna Di Benedetto
Ruggero De Maria
- BioMed Central
Neu im Fachgebiet Onkologie
Mail Icon II